Program at a Glance

Wednesday, 1 August 2018


 09h30 – 12h30

  Riverbank Room 6A & 6B

Royal Australian College of Physicians-Supervisors Training Workshop

Workshop 1 – Practical Skills for Supervisors

Workshop 2 –Work-based Learning and Assessment

Mandatory Supervisors’Training. For medical Oncology Consultants who are registered with the College to attend.


10h00 – 14h00

   City Room 1

Communications Skills Training

For Medical Oncology Trainees who have registered with MOGA to attend

12h30 – 15h30

   City Room 2

Trainees Education Program

For Medical Oncology Trainees who have registered with MOGA to attend

 Co Chair: Dr Brian Stein and Dr Li Chia Chong

Topic 1. How to organize your first research project. Presenter – Prof Martin Stockler (Duration 30 minutes)

Topic 2. Understanding clinical trials and research – starting from the laboratory. Presenter – Professor Claire Scott (Duration 30 minutes)

Topic 3. Career pathways in oncology (Public / Private / Research / Industry). Presenters – Prof Fran Boyle, Dr Amanda Goldrick, Prof Paul De Souza and Dr Peter Tobin (Duration 90 minutes) 

Topic 4. EviQ. Presenter: Dr Brian Stein (Duration 30 minutes)

12h30 – 15h30

   City Room 3

Young Oncologist Group of Australia Program

For Medical Oncology Consultants who have received their FRACP within the past 5 years and have registered with  MOGA to attend

  Co-Chair: Dr Amitesh Roy, Dr Michail Charakidis

Topic 1. Burnout amongst young oncologist. How to recognise it and ways to avoid it. Presenter: Dr Maria Ftanou

Topic 2. Working in rural centres, a challenge and an opportunity. You should consider it. Presenter: Dr Florian Honeyball

Topic 3. How to critically appraise data from clinical trials in the era of cancer drug race? Presenter: Prof Martin Stockler

Topic 4. Is the tele-trial model going to assist with access to clinical trials for rural and remote sites? Presenter: Dr Abhishek Joshi

Open Forum – YOGA – How to move forward

16h00 – 16h50

   Hall N

Industry Symposium 1: PARP inhibitors as maintenance treatment for PSR OC – a review of the evidence

  Chair: Prof Michael Friedlander

Presenter: Prof Nicoletta Colombo

17h00 – 17h50

   Hall N

Industry Symposium 2: Navigating Challenges in 2nd-line NSCLC: How do we best inform our patients about treatment choices and outcomes in the era of immunotherapy?

  Chair: Prof Chris Karapetis

Presenters: Dr David Gandara & A/Prof Rina Hui

18h00 – 19h00

   Hall L

Welcome Reception


Thursday, 2 August 2018


07h30 – 08h30

   Room L1

Breakfast Session 1: Immune-related Adverse Events / Toxicity

Chair: Dr Michail Charakidis
Presenters: A/Prof Jarushka Naidoo

07h30 – 08h30

   Room L2

Breakfast Session 2: Post Ovarian Cancer Consensus

Chair: Prof Michael Friedlander
Presenters: Prof Nicoletta Colombo

07h30 – 08h30

  Panorama 1

Breakfast Session 3: Toward the path of precision oncology with Comprehensive Genomic Profiling

Chair: Dr Amitesh Roy
Presenters: Dr David Gandara and A/Prof Linda Mileshkin

08h50 – 10h00

   Hall N

Opening Ceremony: With National Rural Health Commissioner Professor Paul Worley
Co-Chair: Prof Tim Price & Prof Chris Karapetis

ASM Keynote Address: The Future of Immunotherepy in RCC
Chair: Prof Tim Price & Prof Chris Karapetis
Presenters: Dr Bernard Escudier

10h00 – 11h00

   Hall N

Cancer Achievement Award Presentation: Dose, an overlooked aspect of personalised cancer therapy

Chair: Prof Chris Karapetis
Presenters: Prof Stephen Ackland, 2018 Cancer Achievement Award Recipient 

11h00 – 11h30

   Hall L

Morning Tea & Refreshments

11h30 – 12h45

   Hall N

Symposium 1: Lung
Chair: Prof Ken O’Byrne

Topic 1: Advances in Mesothelioma
Presenter: Professor Anna Nowak    

Topic 2: Stage III Disease – Where are we now?
Presenter: Dr Jack West

Topic 3: Moving forwards with locally advanced lung cancer – a radiotherapy perspective
Presenter: A/Prof Shankar Siva

12h45 – 14h00

   Hall L

Lunch Break

13h15 – 13h45

   Hall N

Medical Oncoloy Group of Australia’s Annual General Meeting

14h00 – 15h00

   Hall N

Oral Presentation Session 1: Trainees’ Proffered Papers
Chair:  Dr Michail Charakidis 

Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP)
Presenter: Dr Nazim Abbas

Single versus multi-dose dexamethasone-premedication for docetaxel chemotherapy: practice and outcomes at Eastern Health
Presenter: Dr Joanna Chan

A review of outcomes for Tasmanian patients with metastatic non-small cell lung cancer treated with nivolumab on the access program
Presenter: Dr Ciara Conduit

Predictors of early deterioration following chemotherapy in patients with small cell lung cancer
Presenter: Dr Mandalina Oprea|

Patterns of patient-reported chemotherapy induced peripheral neuropathy in colorectal cancer survivors: a single institution snapshot
Presenter: Dr Christina Teng

15h00 – 16h00

   Hall N

Symposium 2: Biomarker Assessment and Molecular targeted Therapy
Chair: Dr Rachel Roberts-Thomson

Topic 1. Circulating DNA.
Presenter – Prof Ben Solomon

Topic 2. EGFR. 
Presenter – A/Prof Tom John

Topic 3. PDL1, TMB and Beyond.
Presenter – Dr Jack West

16h00 – 16h30

   Hall L

Afternoon Tea & Refreshments

16h30 – 17h30

   Hall N

Plenary Session: Best of the Best Research in 2018
Chair: Professor Bogda Koczwara AM  

Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: What survival benefits make longer chemotherapy worthwhile?
Presenter: Dr Prunella Blinman

Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Professor Lisa Horvath

PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Professor Martin Stockler

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
Presenter: Dr Shahneen Sandhu

Pre-operative circulating tumour DNA (ctDNA) predicts outcome in resectable stage III melanoma
Presenter: Dr Jenny Lee

17h30 – 18h30

   Hall L

Poster Walk and Talk with Refreshments


19h00 – 21h00

Banksia Room

Industry Dinner by Seqirus
Presenters: To be advised


19h00 – 21h00

   Crystal Room – Stamform Plaza

Industry Dinner by Pierre Fabre
Presenters: To be advised
Friday, 3 August 2018


07h30 – 08h30

   City Room 1

Breakfast Session 4: Biomarkers and the microbiome
Co-Chair: Dr Brian Stein and Dr Craig Gedye
Presenters: A/Prof Jarushka Naidoo

07h30 – 08h30

   City Room 2

Breakfast Session 5: What is the role of the surgeon in metastatic RCC
Chair: Dr Rohit Joshi
Presenters: Dr Bernard Escudier

07h30 – 08h30

   City Room 3

Breakfast Session 6: 2018 update on CINV (Chemotherapy Induced Nausea & Vomiting) & Treatment of chronic cancer pain
Chair: Dr Nick Murray
Presenters: Prof Dorothy Keefe & A/Prof Michael Franco 


09h00 – 10h30

   Hall N

Symposium 3: Genitourinary
Co-Chair: Prof Ken Pittman and Dr Craig Gedye

Topic 1. Sequencing of treatment in Renal.
Presenter – Dr Bernard Escudier

Topic 2. Prostate Cancer: Is there a correct sequence? 
Presenter – Prof Ian Davis

Topic 3. Receptacle bladder cancer (neo adjuvant vs adjuvant), current practice.
Presenter – Prof. Jeremy Shapiro

10h30 – 11h00

   Hall L

Morning Tea & Refreshments

11h00 – 12h30

   Hall N

Symposium 4: Rare Cancers
Chair: Prof Claire Scott

Topic 1. Delving Into Known and Unknown Aspects of Granulosa Cell Tumors of the Ovary Presenter – Prof Nicoletta Colombo

Topic 2. Germ cell cancer (current gold standard and implications for “survivorship”) 
Presenter – Prof Paul de Souza

Topic 3. Small Cell Lung Cancer.
Presenter – Prof. Michael Millward

12h30 – 13h30

   Hall L

 Lunch Break

13h30 – 14h30

   Hall N

Oral Presentation Session 2: Consultants’ Proffered Papers
Chair:  Dr Amitesh Roy

Health-related quality of life (HRQoL) with pembrolizumab or placebo + pemetrexed + platinum in patients with metastatic non- squamous NSCLC: KEYNOTE-189
Presenter:  A/Prof Rina Hui

Phase 3 randomized EORTC 1325-MG/EYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage iii melanoma
Presenter: A/Prof Muhammad Khattak

Changing treatment landscape in the initial management of metastatic castrate-resistant prostate cancer (mCRPC): an Australian multi-centre retrospective study
Presenter: Dr Edmond Kwan

Predicting chemotherapy toxicity in older adults: comparing the value of the CARG toxicity score with oncologists’ estimates of toxicity based on clinical judgement
Presenter: Dr Erin Moth

What do oncologists think patients with incurable cancer should be told about their prognosis? A survey of medical oncologists in Australia and New Zealand
Presenter: Dr Anuradha Vasista

14h30 – 15h00

   Hall L

 Afternoon Tea & Refreshments

15h00 – 16h30

   Hall N

Symposium 5: Medical Cannabis
Chair: Dr Rob Zeilinski

Topic 1. Clinical Trials and Research (Cannabinoids in Pharmacology).
Presenter – Prof Stephen Clarke

Topic 2. Governance & access to cannabis. 
Presenter – Prof Richard Chye

Topic 3. Cannabis around GBM Pharmacology.
Presenter – Dr Ganessan Kichendasse


Close of Sessions


   Adelaide Oval

 Conference Dinner

Buses will depart from Adelaide Convention Centre

Download Program

On this program you will find full details of events held from Wednesday 1 August through until close of play on Friday 3rd.